News and Announcements
Elixinol products launch in New Zealand following change in legislation
- Published January 23, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Elixinol products are now available to patients in New Zealand.
- The launch of products in new Zealand comes following the change in legislation which removes CBD as a Class B1 controlled drug.
- Patients may now import up to three months supply of CBD with prescriptions.
Elixinol Global Limited (ASX:EXL) is pleased to announce that Elixinol branded cannabidiol (CBD) products are now available on a prescription basis in New Zealand.
The launch of products in new Zealand comes following tthe passage of New Zealand’s Misuse of Drugs (Medicinal Cannabis) Amendment Act in December 2018, which classifies CBD with low levels of THC as prescription medicine and removes CBD as a Class B1 controlled drug.
The Act now recognises CBD as a substance with ‘therapeutic value with little or no psychoactive properties’.
Patients can now import up to three months worth of CBD products with a prescription.
Elixinol’s capsules, topicals and tinctures including liposomes meet the required standard for import into New Zealand.
Paul Benhaim, CEO of parent company EXL, said: ” Now, this change in New Zealand enables Elixinol to ship CBD to patients who have been requesting it for years.
We are delighted to be one of the first companies to supply New Zealand patients with the range our US customers have been benefiting from for years”.
About Elixinol Global Limited (ASX: EXL)
Elixinol Global Limited (ASX: EXL; OTCQX: ELLXF) through its businesses has a global presence in the cannabis industry including hemp-derived CBD dietary supplements, hemp food and wellness products, as well as cultivation and manufacture of medicinal cannabis products.
Company Updates
The Index Approach in Early-Stage Venture Capital: Reconsidered
The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]
The Future Is Now: The Evolution of Dealflow with Wholesale Investor
If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]
Investability of a Startup: A Comprehensive Guide for Angels and High-Net Worth Investors
Venturing into the Startup Scene Let’s dive into the intriguing world of startups. It’s a thrilling ride, isn’t it? Like finding a pearl in an ocean, spotting a promising startup amidst a sea of businesses is no easy task. This guide aims to light the way, focusing on the “The Investability of a Startup: 7 […]
Backed By Leading Investment Groups and Family Offices
